Acquiring Company
Merck
Acquired Company
Prometheus Biosciences
RahwaySan DiegoManufacturingBiotechnologyHealthcareHealth CareDescription
In May 2023, Merck completed its all-cash acquisition of Prometheus Biosciences for $200.00 per share, valuing the company at approximately $10.8 billion. Following the acquisition, trading of Prometheus shares ceased on the Nasdaq. Merck has fully integrated Prometheus’ precision immunology pipeline into its own portfolio, enhancing its capabilities in treating inflammatory diseases.
Who to call at Merck, and when
When Merck changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Merck raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Merck, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Merck. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Merck makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Prometheus Biosciences?
Prometheus Biosciences was acquired by Merck, based in Rahway. The deal was reported on April 16, 2023. Merck is publicly traded (MRK) and operates in Manufacturing.
When did Merck acquire Prometheus Biosciences?
Merck's acquisition of Prometheus Biosciences was reported on April 16, 2023. In May 2023, Merck completed its all-cash acquisition of Prometheus Biosciences for $200.00 per share, valuing the company at approximately $10.8 billion. Following the acquisition, trading of Prometheus shares ceased on the Nasdaq. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Prometheus Biosciences do?
Prometheus Biosciences, Inc. is a privately held biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. It is privately held, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.